Date |
Product |
Disease |
Phase |
Company |
Therapeutic area |
2016-12-30
|
BGB-A317 |
advanced solid tumors |
1 |
BeiGene (China) |
Cancer - Oncology |
2016-12-30
|
ruxolitinib |
graft-versus-host disease |
2 |
Incyte (USA - DE) |
Transplantation |
2016-12-29
|
Resunab™- JBT-101 - (6aR,10aR)-3-(1,1-dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-6H-Dibenzo(b,d)pyran-9-carboxylic acid |
cystic fibrosis |
2 |
Corbus Pharmaceuticals (USA - MA) |
Rare diseases - Genetic diseases |
2016-12-29
|
CV301 in combination with Opdivo® (nivolumab) |
non-small cell lung cancer (NSCLC) |
1-2 |
Bavarian Nordic (Denmark) |
Cancer - Oncology |
2016-12-29
|
ARGX-110 |
acute myeloid leukemia (AML) |
preclinical |
Argen-X (Belgium - The Netherlands) |
Cancer - Oncology |
2016-12-29
|
PH-10 |
psoriasis |
2 |
Provectus Pharmaceuticals (USA - TN) |
Autoimmune diseases - Dermatological diseases |
2016-12-29
|
PV-10 |
melanoma |
1 |
Provectus Pharmaceuticals (USA - TN) |
Cancer - Oncology |
2016-12-28
|
GALE-401 (anagrelide controlled release ) |
essential thrombocythemia |
3 |
Galena Biopharma (USA - OR) |
|
2016-12-27
|
Sollpura® (liprotamase) |
cystic fibrosis patients with exocrine pancreatic insufficiency |
3 |
Anthera Pharmaceuticals (USA - CA) |
Rare diseases - Genetic diseases |
2016-12-27
|
sacituzumab govitecan (IMMU-132) |
triple-negative breast cancer |
2 |
Immunomedics (USA - NJ) |
Cancer - Oncology |
2016-12-27
|
MYL-1401O - biosimilar version of trastuzumab |
breast cancer |
3 |
Mylan (USA - PA) Biocon (India) |
Cancer - Oncology |
2016-12-26
|
MGD011 (JNJ-64052781) |
relapsed or refractory B-cell malignancies, including diffuse-large B cell lymphoma, follicular lymphoma, mantle-cell lymphoma, chronic lymphocytic leukemia and acute lymphoblastic leukemia |
1 |
Janssen Biotech, a J&J company (USA - NJ) |
Cancer - Oncology |
2016-12-23
|
Aravive-S6 |
|
preclinical |
Aravive Biologics (USA - TX) |
Cancer - Oncology |
2016-12-23
|
|
choroideremia |
observational |
4D Molecular Therapeutics (USA - CA) |
Rare diseases - Genetic diseases - Ophtalmological diseases |
2016-12-23
|
Jetrea® (ocriplasmin) |
posterior vitreous detachment (PVD) in patients with non-proliferative diabetic retinopathy (NPDR) |
2 |
Thrombogenics (Belgium) |
Ophtalmological diseases |
2016-12-22
|
ND0612H (levodopa and carbidopa administered through a pump patch) |
Parkinson's disease |
2 |
Neuroderm (Israel) |
Neurodegenerative diseases |
2016-12-22
|
BHV-4157 |
spinocerebellar ataxias |
2-3 |
Biohaven Pharmaceuticals (USA - CT) |
Rare diseases - Neurodegenerative diseases - Neurological diseases |
2016-12-22
|
linaclotide colonic release-2 (CR2) formulation |
irritable bowel syndrome with constipation (IBS-C) |
2b |
Ironwood Pharmaceuticals (USA - MA) Allergan (Ireland) |
Inflammatory diseases - Gastrointestinal diseases |
2016-12-21
|
Soliris® (eculizumab) |
delayed graft function |
2-3 |
Alexion Pharmaceuticals (USA - CT) |
Cancer - Oncology |
2016-12-21
|
CTP-656 (D9-ivacaftor ) deuterated ivacaftor |
cystic fibrosis |
2 |
Concert Pharmaceuticals (USA - MA) |
Rare diseases - Genetic diseases |